Table 1S. Related adverse events, any grade and grades 3/4

| *System Organ Class* | *Preferred Term* |  | |  | |
| --- | --- | --- | --- | --- | --- |
| *Total* | | | |
| *Any grade* | | *Grade 3/4* | |
| **N** | **%** | **N** | **%** |
| Blood and lymphatic system disorders | Anemia | 30 | 57 | 23 | 43 |
|  | Febrile bone marrow aplasia | 2 | 4 | 1 | 2 |
|  | Febrile neutropenia | 7 | 13 | 3 | 6 |
|  | Granulocytopenia | 2 | 4 | 2 | 4 |
|  | Granulocytosis | 1 | 2 | 1 | 2 |
|  | Leukopenia | 40 | 75 | 40 | 75 |
|  | Lymphopenia | 11 | 21 | 10 | 19 |
|  | Neutropenia | 24 | 45 | 23 | 43 |
|  | Pancytopenia | 3 | 6 | 3 | 6 |
|  | Thrombocytopenia | 44 | 83 | 43 | 81 |
| Cardiac disorders | Left ventricular dysfunction | 1 | 2 | 1 | 2 |
| Eye disorders | Eye haemorrhage | 1 | 2 | 1 | 2 |
| Gastrointestinal disorders | Colitis | 2 | 4 | 2 | 4 |
|  | Constipation | 9 | 17 | 0 | 0 |
|  | Diarrhea | 18 | 34 | 3 | 6 |
|  | Melaena | 1 | 2 | 1 | 2 |
|  | Nausea | 30 | 57 | 1 | 2 |
|  | Stomatitis | 3 | 6 | 1 | 2 |
|  | Vomiting | 16 | 30 | 1 | 2 |
| General disorders | Asthenia | 6 | 11 | 0 | 0 |
|  | Fatigue | 22 | 42 | 0 | 0 |
|  | Mucosal inflammation | 14 | 26 | 4 | 8 |
|  | Pyrexia | 13 | 25 | 1 | 2 |
| Infections and infestations | Bronchopulmonary aspergillosis | 1 | 2 | 1 | 2 |
|  | Cystitis | 1 | 2 | 1 | 2 |
|  | Device-related infection | 1 | 2 | 1 | 2 |
|  | Gastroenteritis | 1 | 2 | 1 | 2 |
|  | Oesophageal candidiasis | 2 | 4 | 1 | 2 |
|  | Pneunomia | 5 | 9 | 2 | 4 |
|  | Pneunomia influenzal | 1 | 2 | 1 | 2 |
|  | Sepsis | 2 | 4 | 2 | 4 |
|  | Neutropenic sepsis | 2 | 4 | 1 | 2 |
| Investigations | Alanine aminotransferase increased | 6 | 11 | 3 | 6 |
|  | Aspartate aminotransferase increased | 4 | 8 | 2 | 4 |
|  | Blood cholesterol increased | 7 | 13 | 2 | 4 |
|  | Blood lactate dehydrogenase increased | 5 | 9 | 1 | 2 |
|  | Blood urea increased | 2 | 4 | 1 | 2 |
|  | C-reactive protein increased | 5 | 9 | 2 | 4 |
|  | ECOG performance status worsened | 1 | 2 | 1 | 2 |
|  | Gamma-glutamyltransferase increased | 4 | 8 | 2 | 4 |
|  | Glomerular filtration rate decreased | 1 | 2 | 1 | 2 |
|  | Lymphocyte count decreased | 1 | 2 | 1 | 2 |
|  | Neutrophil count decreased | 2 | 4 | 2 | 4 |
|  | Platelet count decreased | 1 | 2 | 1 | 2 |
|  | Weight decreased | 10 | 19 | 0 | 0 |
|  | White blood cell count decreased | 3 | 6 | 3 | 6 |
| Metabolism and nutrition disorders | Decreased appetite | 12 | 23 | 0 | 0 |
|  | Dehydration | 1 | 2 | 1 | 2 |
|  | Hypertriglyceridaemia | 6 | 11 | 2 | 4 |
|  | Hypocalcaemia | 3 | 6 | 1 | 2 |
|  | Hypokalaemia | 13 | 25 | 8 | 15 |
|  | Tumour lysis syndrome | 1 | 2 | 1 | 2 |
| Musculoskeletal and connective tissue disorders | Back pain | 4 | 8 | 1 | 2 |
| Nervous system disorders | Dizziness | 7 | 13 | 0 | 0 |
|  | Dysgeusia | 9 | 17 | 0 | 0 |
|  | Headache | 11 | 21 | 0 | 0 |
|  | Polyneuropathy | 6 | 11 | 0 | 0 |
| Renal and urinary disorders | Renal failure | 5 | 9 | 2 | 4 |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | 9 | 36 | 3 | 6 |
| Skin and subcutaneous tissue disorders | Alopecia | 2 | 4 | 1 | 2 |
|  | Angioedema | 1 | 2 | 1 | 2 |
| Vascular disorders | Brachiocephalic vein thrombosis | 1 | 2 | 1 | 2 |
|  | Hypertension | 4 | 8 | 1 | 2 |
|  | Jugular vein thrombosis | 1 | 2 | 1 | 2 |
|  | | | | |  |
| Selection: Only adverse events Grade 3/4 or with a frequency > 10% of patients are shown. | | | | |  |